Eagle Pharmaceuticals, Inc. (EGRX) SEC Filing 8-K Material Event for the period ending Thursday, June 9, 2022

Eagle Pharmaceuticals, Inc.

CIK: 827871 Ticker: EGRX

View differences made from one to another to evaluate Eagle Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Eagle Pharmaceuticals, Inc..


Assess how Eagle Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Eagle Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Eagle Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Ticker: EGRX
CIK: 827871
Form Type: 8-K Corporate News
Accession Number: 0001104659-22-069521
Submitted to the SEC: Thu Jun 09 2022 8:33:46 AM EST
Accepted by the SEC: Thu Jun 09 2022
Period: Thursday, June 9, 2022
Industry: Pharmaceutical Preparations
  1. Change in Assets
  2. Financial Exhibit
  3. New Agreement
  4. New Financial Obligation
  5. Regulated Disclosure
  6. Unregistered Sales

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: